Abstract
The retroviral vector is widely used in gene therapy, and it has shown its efficacy in the treatment of several infants with severe combined immunodeficiency (SCID)-X1. The current process for producing retroviral vectors with adherent packaging cell lines is costly, labor-intensive, and ineffective in producing high amount of vectors needed for clinical trials. The large-scale production of high- titer clinical grade retroviral vectors could benefit from retrovirus packaging cell lines that could grow in suspension and serum free media.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
